MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Breaking: HeartWare wins FDA nod for bridge-to-transplant heart pump

Breaking: HeartWare wins FDA nod for bridge-to-transplant heart pump

By

HeartWare International logo

Framingham, Mass.-based cardiac device maker HeartWare International (NSDQ:HTWR) won FDA premarket approval for its HeartWare ventricular assist system as a bridge to heart transplantation.

The HeartWare system includes an implantable pump, external driver and power source that can be used either inside or outside of hospitals, the FDA noted.

"For patients awaiting a donor heart, the HeartWare System provides a new treatment option," FDA Center for Devices & Radiological Health director Christy Foreman said in prepared remarks.

HeartWare representatives did not immediately return requests for comment.

Where other devices require pump components be placed in the abdomen, the HeartWare system fits in a small implant near the heart, which makes the device an option for smaller patients or those unable to have an implant in the abdomen, according to the federal watchdog agency.

"The FDA approved the HeartWare LVAD based on data from a clinical trial known as the ADVANCE trial," according to the agency notice. "The trial compared outcomes from 137 advanced heart failure participants using the HeartWare System with outcomes from similar patients followed by the Interagency Registry for Mechanically Assisted Circulatory Support."

This marks the 1st time the FDA has approved a left ventricular assist device based on clinical trials that relied on data as a control, the FDA noted.

HeartWare last month backed out of its REVIVE-IT study assessing the LVAD system in less-sick patients. HeartWare had contributed $600,000 to the study, and the company said at the time that it needed to focus efforts on winning FDA approval for the device.

"Following the positive recommendation of the Circulatory System Devices Advisory Committee in the 2nd quarter, we have been focused on working with the FDA as it finalizes its review of our premarket approval application for U.S. commercialization of the HeartWare ventricular assist system as a bridge to heart transplantation," president & CEO Doug Godshall said at the time.

Godshall added that the company plans to launch the HeartWare system and HVAD pump all around the world.

Earlier this month HeartWare reported its Q3 earnings, reporting strong growth in sales but deeply widening losses.

In case you missed it

RSS From Medical Design & Outsourcing

  • Intuitive Surgical highlights supply chain risk, addresses Medtronic’s Hugo launch
    Intuitive Surgical executives today said delays and price increases are working their way through the medtech supply chain, likely resulting in higher production costs in the months ahead and the potential for delayed development and regulatory activity. “I don’t think I can say it’s getting better. It’s a difficult situation and will continue for some… […]
  • Intuitive Surgical names new C-suite leaders, reports Street-beating Q3
    Intuitive Surgical (NSDQ:ISRG) today announced changes in the ranks of its senior leadership as the surgical robotics maker released Q3 results that exceeded expectations. Sunnyvale, California-based Intuitive launched two new functional organizations — Strategy and Growth, and Global Business Services — and named leaders who will take over effective Jan. 1. Dave Rosa, a 25-year… […]
  • Johnson & Johnson discloses two-year delay for Ottava robot
    Johnson & Johnson (NYSE:JNJ) today confirmed that it experienced a “temporary setback” with its Ottava surgical robotic system. Speaking on the company’s third-quarter earnings call, transcribed by SeekingAlpha, J&J EVP Joseph Wolk said that while the company maintains its commitment to developing a general surgery offering with Ottava, the platform’s development timeline has been pushed back about two years… […]
  • BICO’s Cytena launches C.Station automated cell line development platform for antibody and gene therapies
    BICO Group subsidiary Cytena today announced the launch of its C.Station platform for automating the development of stable cell lines. Cytena said in a news release that C.Station is a user-friendly platform that covers the entire cell line development workflow, from single-cell cloning of transfected cells to the selection of high-producing clones and upscaling. Cytena… […]
  • Tungsten cable for surgical robotics: A complex material serving a complex application
    Tungsten mechanical cables are the most popular for surgical robot makers. Connor Chiuchiolo and Scott Dailey, Carl Stahl Sava Industries The mechanical cables that reside within the motion control systems of the most modern surgical robots can be so small that the individual filaments themselves are nearly impossible to see with the naked eye. So… […]
  • Phillips-Medisize expands its global manufacturing capacity
    Phillips-Medisize announced today that it expanded its global manufacturing capacity through several collaborations and internal initiatives. Hudson, Wisconsin-based Phillips-Medisize, a Molex company, said its global reach now encompasses 36 facilities with scalable, end-to-end capabilities tailored to help customers bring products to market quickly and efficiently from anywhere in the world. “As the preferred partner for… […]
  • OmniVision launches cable modules for single-use endoscopes, catheters
    OmniVision Technologies today announced that it has launched its OVMed OCHSA and OCHTA cable modules for single-use endoscopes and catheters. The Santa Clara, California-based company designed the medical-grade imaging subsystems with a small diameter camera module that is fully integrated with OVMed cables and mini-LED illumination. Get the full story on our sister site, Medical… […]
  • Machine Bio wins first BioTools Innovator competition
    The new BioTools Innovator accelerator program awarded its first $200,000 grand prize to Machine Bio after a live vote last week. Claremont, California-based startup Machine Bio was founded by David Marash, who serves as CEO.  “Machine Bio’s mission is to develop and commercialize a transformative protein expression platform that drastically minimizes the process of making… […]
  • Hologic CEO Steve MacMillan salutes CFO Karleen Oberton, offers his outlook and talks M&A
    After interviewing Hologic CFO Karleen Oberton for Medical Design & Outsourcing‘s annual Women in Medtech issue, we connected with CEO Steve MacMillan to get his take. He offered praise for his finance chief’s leadership throughout the pandemic, shared his outlook for the Marlborough, Massachusetts–based company’s future and discussed the M&A strategy for Hologic (NSDQ:HOLX), which… […]
  • Forecasting the future of urology with Boston Scientific’s Meghan Scanlon
    Meghan Scanlon, Boston Scientific’s president of urology and pelvic health, discusses the field and the challenges and opportunities ahead. The urology specialty faces a critical moment, with 10 urologists ready to retire for every new urologist entering the field, said Meghan Scanlon, SVP and president of urology and pelvic health at Boston Scientific (NYSE:BSX) That… […]
  • Women researchers receive a fraction of funding from the world’s biggest medtech companies
    The gender divide in medtech extends beyond leadership and into funding for investigational studies by U.S. physicians. Only 6.7% of physicians who received research payments from the world’s largest medical device companies in 2020 were women, according to an analysis of Medical Design & Outsourcing’s Big 100 list of medtech companies and CMS Open Payments… […]

Leave a Reply